Product
TILD
Aliases
TILD sub-cutaneous (SC) injection
3 clinical trials
1 indication
Indication
Psoriatic ArthritisClinical trial
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)Status: Recruiting, Estimated PCD: 2024-06-01